Aspect Medical Systems Presents Positive Results of BRITE Major Depression Study at Scientific Conferences

  
    
  
  
    
      Aspect Medical Systems, Inc. (NASDAQ: ASPM) will present study results 
      from the BRITE (Biomarkers for Rapid Identification of Treatment 
      Effectiveness) trial in major depression at the Society of Biological 
      Psychiatry and American Psychiatric Association Annual Meetings in 
      Washington D.C. this week. BRITE trial results demonstrate that Aspect’s 
      EEG-based Antidepressant Treatment Response (ATR) indicator is a 
      significant predictor of patient response and remission when used after 
      one week of treatment with the antidepressant escitalopram. An economic 
      analysis using the BRITE data to model the potential health economic 
      impact of ATR-guided treatment will also be presented this week at the 
      annual meeting of the International Society for Pharmacoeconomics and 
      Outcomes Research (ISPOR) in Toronto.
    
    
      “We are pleased that the results of the BRITE 
      trial indicate that early changes in frontal EEG signals carry important 
      information about future clinical response, as this reinforces our 
      confidence that an EEG-based biomarker has the potential to help 
      clinicians improve the care of patients suffering from depression,” 
      said Andrew Leuchter, M.D., professor of Psychiatry at the Semel 
      Institute for Neuroscience and Human Behavior at UCLA, principal 
      investigator for the trial, and chair of Aspect’s 
      Neuroscience Advisory Board.
    
    
      The BRITE trial was conducted in collaboration with leading 
      investigators from 10 facilities across the United States and enrolled 
      375 patients. Patient response was defined by researchers as a 50 
      percent improvement in depression symptoms as measured by the Hamilton 
      Depression Rating Scale (HAM-D) after seven weeks of treatment, and 
      remission was defined as recovery from depression (HAM-D